Skip to content

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06880627
Enrollment
66
Registered
2025-03-18
Start date
2025-04-16
Completion date
2027-06-01
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Keywords

Cognitive issues, Memory or Focus problems, Internet connected devices, Online group sessions, Online brain games, Surveys

Brief summary

The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being. The study team hypothesize that participants that receive the intervention will have better improvements immediately after treatment at week 8 in all cognitive function measures, non-cognitive symptoms, and self-management compared to those in the waitlist control.

Interventions

BEHAVIORALBrain Boost group

There will be 8 group educational sessions over an 8-week program period to learn strategies for improving cognitive function. Participants will also be asked to engage in 20 minutes, at least 5 times per week online game-like cognitively stimulating activities to improve cognitive health. In addition, surveys will be completed as certain timepoints.

This group will continue to receive usual health and care routines. Participants will be asked to complete surveys at certain timepoints that are the same as the boost group. After the 6-month follow-up, participants will receive the intervention materials, which include 8 weekly educational session recordings with slides, 8 weeks' subscription to online brain games, and biweekly online office hours. The office hours, hosted by the principal investigator and a trained patient co-facilitator, will give participants a chance to discuss participant's progress and ask questions.

Sponsors

University of Michigan
Lead SponsorOTHER
National Scleroderma Foundation
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Have physician-diagnosis of Systemic sclerosis (SSc) (any subtype) * A score of ≥ 10 on the Perceived Deficits Questionnaire * A score of ≤ 7 on the 6-Item Cognitive Impairment Test * Have access to a reliable, internet-connected device (e.g. computer, smartphone, tablet) * Visual acuity with correction sufficient to work on a computer, smartphone, tablet or screen * Be able to read, speak, and understand English

Exclusion criteria

* Diagnosis of dementia or head injury * Other neurological disorders that might impact cognition * Have major psychiatric disorder such as major depression and schizophrenia * Complex, unstable health issues that would preclude full participation in the study (like a planned surgery or active cancer treatment)

Design outcomes

Primary

MeasureTime frameDescription
Change in objective cognitive function from baseline to week 8Baseline, 8 weeksThis will be assessed using the online platform BrainCheck. The following tests will be included: (1) Trail Making A \& B (attention and mental flexibility); (2) Stroop Color and Word test (executive function); (3) Digit-Symbol Substitution (processing speed); and (4) Immediate and Delayed Recognition tests (memory). A composite score will be calculated through BrainCheck to assess global cognitive function. The score range is 0-200 a higher score means greater cognitive function.

Secondary

MeasureTime frameDescription
Change in perceived cognitive function will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) cognitive function ability 4a short formBaseline, 8 weeksThe PROMIS short form evaluates concentration, sharpness, thinking speed, and memory functioning over the past 7 days on a 5-point Likert scale (1 = not at all to 5 = very much). The scores range from 4-20 with higher score indicating higher cognitive functioning. All PROMIS raw scores will be converted to T-scores, where a higher score indicates a greater degree of the domain assessed.
Change in pain will be measured using the PROMIS pain interference short formBaseline, 8 weeksThis is a 4-item short form which assesses pain interference with daily activities, work around the home, social activities, and household chores on a 5-point Likert scale (1 = not at all to 5 = very much). The scores range from 4-20 with higher score indicating higher pain interference. All PROMIS raw scores will be converted to T-scores, where a higher score indicates a greater degree of the domain assessed.
Change in fatigue will be measured using the PROMIS fatigue short formBaseline, 8 weeksThis is a 4-items short form which evaluates individuals' fatigue experience and its impact on participant's everyday lives using a 5-point Likert scale (1 = not at all to 5 = very much). The scores range from 4-20 with higher score indicating more fatigue. All PROMIS raw scores will be converted to T-scores, where a higher score indicates a greater degree of the domain assessed.
Change in depressed mood will be measured using the PROMIS depression short formBaseline, 8 weeksThis is a 4-item short form which assesses feelings of worthlessness, helplessness, depressed mood, and hopelessness on a 5-point Likert scale (1 = Never to 5 = Always). The scores range from 4-20 with higher score indicating more depressed mood. All PROMIS raw scores will be converted to T-scores, where a higher score indicates a greater degree of the domain assessed.
Change in self-management will be evaluated using the Patient Activation Measure (PAM)Baseline, 8 weeksThis is a 13-item measure that assesses patient knowledge, skill, and confidence. Each item is scored from 1 (strongly disagree) to 4 (strongly agree). Scores range from 13 to 52, with higher scores indicating greater confidence and knowledge in patients managing participant's condition.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORYen Chen, PhD

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026